Dnaprint Genomics Stock Performance
| DNAG Stock | USD 0.00001 0.00 0.00% |
The firm owns a Beta (Systematic Risk) of 0.0, which means not very significant fluctuations relative to the market. the returns on MARKET and DNAPrint Genomics are completely uncorrelated.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in DNAPrint Genomics are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. Despite nearly weak basic indicators, DNAPrint Genomics reported solid returns over the last few months and may actually be approaching a breakup point. ...more
Last Split Factor 1:20 | Last Split Date 2005-07-12 |
DNAPrint Genomics Relative Risk vs. Return Landscape
If you would invest 0.00 in DNAPrint Genomics on November 2, 2025 and sell it today you would earn a total of 0.00 from holding DNAPrint Genomics or generate 9.223372036854776E16% return on investment over 90 days. DNAPrint Genomics is currently generating 16.3934% in daily expected returns and assumes 128.0369% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than DNAPrint, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
DNAPrint Genomics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of DNAPrint Genomics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for DNAPrint Genomics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| DNAPrint Genomics is way too risky over 90 days horizon | |
| DNAPrint Genomics has some characteristics of a very speculative penny stock | |
| DNAPrint Genomics appears to be risky and price may revert if volatility continues | |
| DNAPrint Genomics has high likelihood to experience some financial distress in the next 2 years | |
| DNAPrint Genomics currently holds 240 K in liabilities. DNAPrint Genomics has a current ratio of 0.17, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about DNAPrint Genomics' use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 2.43 M. Net Loss for the year was (12.35 M) with profit before overhead, payroll, taxes, and interest of 446.37 K. | |
| DNAPrint Genomics currently holds about 134.35 K in cash with (5.78 M) of positive cash flow from operations. | |
| DNAPrint Genomics has a frail financial position based on the latest SEC disclosures |
DNAPrint Genomics Fundamentals Growth
DNAPrint Stock prices reflect investors' perceptions of the future prospects and financial health of DNAPrint Genomics, and DNAPrint Genomics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on DNAPrint Stock performance.
| Return On Asset | -1.05 | ||||
| Profit Margin | (2.36) % | ||||
| Operating Margin | (7.31) % | ||||
| Current Valuation | 5.64 M | ||||
| Price To Sales | 0.20 X | ||||
| Revenue | 2.43 M | ||||
| Gross Profit | 446.37 K | ||||
| EBITDA | (5.78 M) | ||||
| Net Income | (12.35 M) | ||||
| Cash And Equivalents | 134.35 K | ||||
| Total Debt | 240 K | ||||
| Current Ratio | 0.17 X | ||||
| Book Value Per Share | (0.01) X | ||||
| Cash Flow From Operations | (5.78 M) | ||||
| Market Capitalization | 386.76 K | ||||
| Total Asset | 10.27 M | ||||
| Retained Earnings | (45.53 M) | ||||
| Working Capital | (9.35 M) | ||||
| Current Asset | 1.89 M | ||||
| Current Liabilities | 11.24 M | ||||
About DNAPrint Genomics Performance
By analyzing DNAPrint Genomics' fundamental ratios, stakeholders can gain valuable insights into DNAPrint Genomics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if DNAPrint Genomics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if DNAPrint Genomics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 24.11 | 22.90 | |
| Return On Tangible Assets | (1.11) | (1.16) | |
| Return On Capital Employed | 2.28 | 2.13 | |
| Return On Assets | (1.08) | (1.14) | |
| Return On Equity | 3.83 | 4.02 |
Things to note about DNAPrint Genomics performance evaluation
Checking the ongoing alerts about DNAPrint Genomics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for DNAPrint Genomics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| DNAPrint Genomics is way too risky over 90 days horizon | |
| DNAPrint Genomics has some characteristics of a very speculative penny stock | |
| DNAPrint Genomics appears to be risky and price may revert if volatility continues | |
| DNAPrint Genomics has high likelihood to experience some financial distress in the next 2 years | |
| DNAPrint Genomics currently holds 240 K in liabilities. DNAPrint Genomics has a current ratio of 0.17, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about DNAPrint Genomics' use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 2.43 M. Net Loss for the year was (12.35 M) with profit before overhead, payroll, taxes, and interest of 446.37 K. | |
| DNAPrint Genomics currently holds about 134.35 K in cash with (5.78 M) of positive cash flow from operations. | |
| DNAPrint Genomics has a frail financial position based on the latest SEC disclosures |
- Analyzing DNAPrint Genomics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether DNAPrint Genomics' stock is overvalued or undervalued compared to its peers.
- Examining DNAPrint Genomics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating DNAPrint Genomics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of DNAPrint Genomics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of DNAPrint Genomics' stock. These opinions can provide insight into DNAPrint Genomics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for DNAPrint Stock analysis
When running DNAPrint Genomics' price analysis, check to measure DNAPrint Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DNAPrint Genomics is operating at the current time. Most of DNAPrint Genomics' value examination focuses on studying past and present price action to predict the probability of DNAPrint Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DNAPrint Genomics' price. Additionally, you may evaluate how the addition of DNAPrint Genomics to your portfolios can decrease your overall portfolio volatility.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |